Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Trial of Autologous T Cells Engineered to Express NY-ESO-1 TCR and CRISPR Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T Cells)

NCT03399448 is registered in ClinicalTrials.gov with University of Pennsylvania as lead sponsor.

NCT NCT03399448
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03399448 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Trial of Autologous T Cells Engineered to Express NY-ESO-1 TCR and CRISPR Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T Cells)
Lead sponsor
University of Pennsylvania
Phase
Phase 1
Overall status
Terminated
Start date
September 5, 2018
Completion date
October 9, 2020
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, multiple myeloma, myxoid/round cell liposarcoma, synovial sarcoma